Document is current
Any future updates will be listed below
-
Authors
Peters, Jim
van der Waal, Daniëlle
Schmidt, Marjanka K.
van Gils, Carla H.
Broeders, Mireille J. M.
,
Broeders, Mireille
Dunning, Loes
van Gils, Carla
Karssemeijer, Nico
de Koning, Harry
van Oirsouw, Marja
van Ravesteyn, Nicolien
Schmidt, Marjanka
Verschuur, Ellen
van der Waal, Daniëlle
-
Funding
Funding for this research was provided by:
KWF Kankerbestrijding (12522)
Netherlands Organization for Health Research and Development (40-00812-98-12070)
- License Information
-
More Information
Article History
Received: 20 March 2026
Accepted: 23 July 2026
First Online: 31 July 2026
Ethics
Competing interests: The authors declare the following Financial and Non-Financial Competing Interests: C.vG. is principal investigator of the DENSE trial, financially supported by the University Medical Center Utrecht (UMC Utrecht, UMCU DENSE), the Netherlands Organization for Health Research and Development (ZonMw ZONMW-200320002-UMCU, ZonMW Preventie 50–53125–98–014), KWF Kankerbestrijding (DCS-UU-2009–4348, UU-2014–6859, UU-2014–7151), the Dutch Pink Ribbon/A Sister’s Hope (Pink Ribbon-10074), Bayer AG Pharmaceuticals, Radiology (project number: BSP-DENSE), and Stichting Kankerpreventie Midden-West. C.vG. is also principal investigator of the DENSE-2 trial, financially supported by Dutch Organisation for Knowledge and Innovation in Health, Healthcare and Well-being (ZonMw) (project number: 05550412310002), Bayer, Hologic, and Siemens Healthineers. C.vG. is director of the Dutch Cancer Society. N.K. is board member and shareholder of ScreenPoint Medical and shareholder of Volpara Technology. H.dK. received consulting fees from Bayer (personal). NvR received consulting fees from Wickenstones. M.J.M.B. received grants or has grants pending to institution from ScreenPoint Medical, Sectra Benelux, Hologic, Volpara Solutions, Lunit, and iCAD. M.J.M.B. received speaker fees and travel support to institution from Hologic and Siemens Healthcare.
